P
Über
Philip Scheltens is a Partner and Head of the Dementia Fund at EQT Life Sciences. He is listed as the responsible advisor for NewAmsterdam Pharma, a late-stage biopharmaceutical company focused on metabolic diseases and investigating obicetrapib as a potential treatment for Alzheimer’s disease.
Schwerpunkte
BioTech, HealthTech, Dementia
Verifizierte Kontakte & Outreach Agenten
Direktes E-Mail-Muster
KI Outreach Agenten Pitch Writer
Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...